ライフサイエンスコーパス: multitargeted

1 his non-ATP competitive kinase inhibitor has multitargeted activity, promoting mitotic arrest and apo

2 NF-kappaB activation and their regulation by multitargeted agents in contrast to monotargeted agents,

3 22584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerabi

4 tive flavonol ligands with the aim to obtain multitargeted anticancer agents.

5 is important for development of efficacious multitargeted anticancer drugs.

6 Multitargeted antifolate (MTA) is an investigational age

7 9 colon carcinoma cells was decreased by the multitargeted antifolate (MTA), LY231514.

8 cal isosteric C8-N9 bridged analogues of the multitargeted antifolate LY231514 were synthesized as in

9 Pemetrexed is a multitargeted antifolate with manageable toxicity and ha

10 ill potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of

11 n metastatic prostate cancer will comprise a multitargeted approach aimed at both the tumor cell and

12 A more direct means by which this multitargeted approach can be achieved is by identifying

13 everal pro-permeability proteins providing a multitargeted approach in RVO.

14 A multitargeted approach involving selective local antiang

15 volved in epileptogenesis, it is likely that multitargeted approaches are required for epilepsy preve

16 esponse supports the concept of combination, multitargeted approaches rather than traditional chemoth

17 Our data indicate that multitargeted combinatorial therapies targeting tumor ce

18 Herein we report on a novel series of multitargeted compounds obtained by linking together gal

19 is, and therapeutic effects of the family of multitargeted compounds that simultaneously disrupt func

20 peutic benefits are likely attributed to its multitargeted effects on cerebrovascular patency and int

21 n to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib.

22 Our results indicate that a complex and multitargeted hsa-miRNA response occurs during CMV repli

23 les are brain-penetrant and exhibit balanced multitargeted in vitro activity in the low muM range.

24 nt and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinas

25 then metronomic chemotherapy, overlaid with multitargeted inhibition of PDGFR and VEGFR, gave comple

26 we describe MK-2461, a novel ATP-competitive multitargeted inhibitor of activated c-Met.

27 aling how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.

28 emia (T-ALL) samples and pave the way toward multitargeted JAK1 and JAK3 therapy in T-ALL.

29 The addition of the multitargeted kinase inhibitor midostaurin to standard c

30 Dasatinib is a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family

31 ne kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family

32 Recently, the multitargeted kinase inhibitor sorafenib was shown to be

33 iruses, all of which can be amplified by the multitargeted kinase inhibitor sunitinib.

34 KW-2449 is a novel multitargeted kinase inhibitor that induces cytotoxicity

35 b is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF recept

36 hether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patient

37 Dasatinib is a multitargeted kinase inhibitor that was recently approve

38 tion of a fluorine-18 analog of dasatinib, a multitargeted kinase inhibitor, are reported.

39 The efficacy of sorafenib, a multitargeted kinase inhibitor, in melanoma is still und

40 4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevaciz

41 and complementary approach is the design of multitargeted modulators simultaneously addressing multi

42 itable as a scaffold for the design of novel multitargeted molecules.

43 Here we report that BEZ235, a multitargeted pan-PI3K/dual-mTOR inhibitor, potently kil

44 Of the 11 eyes subjected to PPV, the multitargeted PCR results for tuberculosis were positive

45 Consequently, it seems that multitargeted photoimmunotherapy should also be useful a

46 s hold important implications for the use of multitargeted PI3K inhibitors in the treatment of hemato

47 Vitreous fluid samples were subjected to multitargeted polymerase chain reaction (PCR) for a M. t

48 agents, which can be explained by potential multitargeted properties.

49 ip studies that led to the identification of multitargeted prototypes with activities as MT-stabilizi

50 bination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor,

51 Sunitinib is a multitargeted receptor tyrosine kinase inhibitor approve

52 Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of the

53 SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF

54 with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor resulti

55 ABT-869 (a multitargeted receptor tyrosine kinase inhibitor) inhibi

56 with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor, result

57 or sequential administration of sunitinib, a multitargeted receptor tyrosine kinase inhibitor.

58 Effects of 4 multitargeted receptor tyrosine kinase inhibitors on reg

59 or 8 and 90 revealed that both compounds are multitargeted receptor tyrosine kinase inhibitors with l

60 type 1 infection and no cirrhosis, a 12-week multitargeted regimen of ABT-450/r-ombitasvir and dasabu

61 Treatment with the multitargeted regimen of ombitasvir-ABT-450/r and dasabu

62 RNA targets of multitargeted RNA-binding proteins (RBPs) can be studied

63 SU11657 is a multitargeted selective inhibitor of class III/V recepto

64 ood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 D

65 rylimidazoles provide tools to explore novel multitargeted strategies for AD and other neurodegenerat

66 A multitargeted therapeutic approach using a bile acid seq

67 should encourage further development toward multitargeted therapeutic intervention in HDBC.

68 In this context, the development of single multitargeted therapeutics directed against two or more

69 y represent a novel target in the search for multitargeted therapies based on the HSP90 chaperone sys

70 This has spurred the development of multitargeted therapies, including small molecules that

71 with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antivira

72 images from a phase II study of sunitinib, a multitargeted TKI.

73 Rational development of multitargeted TKIs for prostate cancer requires improved

74 targeted therapies rather than non-specific, multitargeted treatments.

75 Multitargeted tyrosine kinase inhibition has recently sh

76 SU11248 is an oral, selective multitargeted tyrosine kinase inhibitor currently in Pha

77 FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib.

78 The multitargeted tyrosine kinase inhibitor sorafenib is use

79 The novel multitargeted tyrosine kinase inhibitor sunitinib is use

80 Multitargeted tyrosine kinase inhibitor sunitinib reduce

81 Nilotinib, a recently approved multitargeted tyrosine kinase inhibitor targeting the BC

82 lity of sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor that blocks the

83 ial growth factor receptor 2, c-MET, and RET multitargeted tyrosine kinase inhibitor that has antiang

84 Sunitinib is a clinically approved multitargeted tyrosine kinase inhibitor that inhibits va

85 Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits va

86 SU11657, a selective, oral, multitargeted tyrosine kinase inhibitor that targets FLT

87 Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets onc

88 Pazopanib, a multitargeted tyrosine kinase inhibitor, has recently be

89 lity and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients wit

90 Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown

91 staurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrat

92 ated whether a multimodal strategy combining multitargeted tyrosine kinase inhibitors (MTKIs) and mic

93 The multitargeted tyrosine kinase inhibitors Crizotinib and

94 neuregulin, whereas the off-target effect of multitargeted tyrosine kinase inhibitors may be mediated

95 Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approv